Here, the authors report results from a randomized, placebo-controlled phase 3 trial of the tetravalent SARS-CoV-2 protein vaccine SCTV01E, demonstrating a favorable efficacy profile during a time when predominant viral variants were changing from BA.5 and BF.7 to XBB.
- Ruizhi Zhang
- Junshi Zhao
- Liangzhi Xie
